Trinity Biotech shares surge 15.81% premarket after securing $25M standby equity facility with Yorkville to fund HIV diagnostics expansion and CGM+ development.

Trinity Biotech surged 15.81% in premarket trading following the announcement of a $25 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global. The agreement provides discretionary funding over 36 months to advance its HIV diagnostics expansion, CGM+ glucose monitoring development, and other R&D initiatives. The deal allows Trinity to sell American Depositary Shares at a 95–97% discount to recent volume-weighted average prices, offering flexible capital access. Recent commercial momentum, including strong HIV test sales and breakthrough trial results for its needle-free CGM+ sensor, further reinforced investor confidence in the company’s growth trajectory. The financing aligns with CEO John Gillard’s strategic focus on profitable business expansion and innovation, positioning Trinity to capitalize on its transformative pipeline and operational efficiencies.